Department of Radiation Oncology, Beaumont Health, Royal Oak, Michigan.
Department of Clinical Ethics, Beaumont Health, Royal Oak, Michigan.
Pract Radiat Oncol. 2021 Sep-Oct;11(5):e449-e458. doi: 10.1016/j.prro.2021.01.007. Epub 2021 Feb 3.
The purpose of this study was to delineate a scoring system to maximize the ethical allocation of proton beam therapy (PBT) and determine what factors are associated with receipt of PBT, including the role of specific insurance providers.
Our scoring system was developed in collaboration with a multidisciplinary panel of experts. Patients submitted for PBT consideration were assigned a score by committee at a weekly peer-reviewed session at a time when our center was operating at capacity. Univariate analysis and multivariable analysis of initial and final insurance response were performed.
One hundred ninety-seven patients were prospectively reviewed. Ninety-three percent of patients with Medicaid coverage, 88% of patients with Medicare, and 78% of patients with private insurance were ultimately approved for PBT. Median time to final insurance response was 12 days (interquartile range, 9-18 days) for patients who were ultimately denied PBT coverage. Having primary provider C (odds ratio [OR], 14; 95% confidence interval [CI], 1.20-1.96; P = .033) or third party providers A (OR, 4.22; 95% CI, 1.71-10.9; P = .002) or B (OR, 5.28; 95% CI, 1.56-17.2; P = .006) was significantly associated with final insurance denial for PBT on univariate analysis. Total score (OR, 0.79; 95% CI, 0.67-0.90; P = .002) and having coverage through third party provider A (OR, 24.2; 95% CI, 9.51-68.9; P < .001) were associated with final insurance response on multivariable analysis.
Our scoring system was significantly associated with receipt of proton beam therapy. Certain insurance providers are less likely to approve PBT for patients, all else being equal. Such a scoring system could be implemented effectively at other PBT facilities, and additional work is needed in ensuring patients with the most to gain from PBT will be approved by their insurance providers.
本研究旨在制定一个评分系统,以最大化质子束治疗(PBT)的伦理分配,并确定哪些因素与接受 PBT 相关,包括特定保险公司的作用。
我们的评分系统是与一个多学科专家小组合作开发的。在我们的中心满负荷运转时,每周在同行评审会议上,委员会会对提交 PBT 考虑的患者进行评分。对初始和最终保险反应进行单变量分析和多变量分析。
197 名患者进行了前瞻性审查。有医疗补助覆盖的患者中,93%、有医疗保险的患者中,88%、有私人保险的患者中,78%最终获得了 PBT 的批准。最终拒绝 PBT 保险覆盖的患者的最终保险反应中位数时间为 12 天(四分位距,9-18 天)。主要提供者 C(比值比 [OR],14;95%置信区间 [CI],1.20-1.96;P =.033)或第三方提供者 A(OR,4.22;95% CI,1.71-10.9;P =.002)或 B(OR,5.28;95% CI,1.56-17.2;P =.006)有显著关联,在单变量分析中,PBT 的最终保险拒绝。总评分(OR,0.79;95% CI,0.67-0.90;P =.002)和通过第三方提供者 A 获得覆盖(OR,24.2;95% CI,9.51-68.9;P <.001)在多变量分析中与最终保险反应相关。
我们的评分系统与质子束治疗的接受情况显著相关。在其他条件相同的情况下,某些保险公司不太可能批准 PBT 用于患者。这种评分系统可以在其他 PBT 设施中有效实施,还需要做更多的工作,以确保从 PBT 中获益最多的患者得到其保险公司的批准。